Moderna, Inc.

Moderna, Inc. is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna focuses on developing mRNA-based medicines for infectious diseases, oncology, rare diseases, and cardiovascular conditions. Its most notable product is the Spikevax COVID-19 vaccine, which generated significant revenue during the pandemic. The company leverages its proprietary mRNA platform to rapidly design and manufacture new vaccines and therapies.

Moderna's business model centers on research and development of mRNA candidates, with revenue primarily derived from product sales (mainly Spikevax) and government contracts. The company also earns collaboration revenue from partnerships with organizations like the U.S. government and Merck. As of the latest data, Moderna has a market cap of $19.47B, with revenue of $389M in Q1 2026, though it remains unprofitable with negative operating margins. The company holds $1.91B in cash against $590M in debt.

Moderna operates in the highly competitive biotechnology sector, specifically in mRNA technology. Key competitors include Pfizer/BioNTech, CureVac, and traditional vaccine makers like GSK and Sanofi. Moderna's competitive advantage lies in its first-mover status in mRNA vaccines and its robust pipeline of over 40 programs. However, the company faces challenges from declining COVID-19 vaccine demand and high R&D costs, reflected in its negative EBITDA and profit margins.

Moderna's primary customers are governments, healthcare providers, and individuals for its COVID-19 vaccine. Its target audience includes global populations requiring vaccination against infectious diseases. Geographically, Moderna's revenue is heavily concentrated in the U.S., with international sales to Europe, Japan, and other markets. The company is expanding its pipeline to address respiratory viruses, cancer, and rare diseases, aiming to diversify its customer base beyond pandemic-related demand.

An auto-generated descriptive profile based on company data, for informational purposes only.